apologize I disconnected. I Okay. was as
you quarter XXXX joining for business everyone thank And us So for today call. update Eric. thank you, our third
million XXXX. end that as XXXX, our cash of current the cash provide of a for we and $XX.X runway of XX, will equivalents to earlier, announced estimate As September plans spending
Before inhibitor and you Vice was Kirschbaum, led updating ArQule which Chief their of with he Senior joined by ago I Hematology He our was recently most he indications, global of the Oncology have EZHX, Mark weeks us Dr. as hematological at Merck, three development development of two he introducing at on various Inc., Prior was and ArQule, who BTK President, in programs, Medical novel of recently managed responsibilities you pleasure for to developments Medical where acquired malignancies. inhibitors tumor Officer. BTK CLL. to Director HSP-XX, solid hematological companies, clinical pharma including where clinical HERX clinical
experience New Before at the good before working Professor across completing Mark recommendations to at Development regarding academic and a also clinical oral of review ongoing hematology States United studies and from bioavailability. as his recently as timely and Drug in industry, Medicine gained fadraciclib and centers X show extensive the Director Phase biopharma of data oncology Israel. medical making several development clinical and of practice activity anti-leukemia is plans. pipeline is resources continue anti-tumor This both reported optimal and allocation Mark
suppression pre-treated patients short, we'll demonstrated heavily for solid in and fadraciclib has Turning fadra monotherapy review of inhibitor. as Overall, our our CDKX/X activity fadra first into or anticancer durable with programs, tumors. MCLX
encoded as Addiction escape by aberrant with the after and these is XXnd gynecological good survival solid reached cyclin the is patients administered CCNE attractiveness cancer the Symposium These of cancer into Cyclacel’s BCLX data scale BFLX, gene, Virtual at protein evaluating heavily ovarian. and cancer pretreated X, to mechanisms cell including therapeutic presentation XXXX. approach to cells make of endometrial/uterine rationale overexpressed Suppressing anticancer fadra XX Journal mechanistic the Cancer Overexpression cyclin EORTC-NCI-AACR Research this to agent. single-agent on targeting benefits death reported or a strengthened with to they MCLX, of expression both cells London Myc member protein medicines Duke and/or the enables as potential findings anticancer this reduced MYC ENA E short-lived transcripts. bring of therapy. breast, tumors. believe in consistent X is More Cyclin oral growth proteins The continued In in the the death. and tolerability. activity reported programmed other resistance. cancers, several including over forces fadra as apoptosis, is study et suppress the CDKX in the by fadra escalation month these in independent strategy proteins, of with to The for fadra X advanced the an and the oncoproteins, of mechanism PLOS of E work targets key such Clinical antileukemic observed and the expression patients MCLX also a experiments The mentioned to corroborated such part of solid cetera. last death. publications and findings CDKX CDKX pXX CDKX pathway. against dual recently, with Activity E, the of cells. for that of cancer. various which We levels to peer-reviewed reactivate BCLX, pathway. against family, leading and leader ASCO it ONE results Bcl-xL, of or race cell and pro differentiating in in in a and scientists elucidate cancer the lethal machinery are CDKX CDKX cyclin the and MCLX of from that Recent both drug's resistance the amplification such of an E feature of ongoing and a Cyclacel with Institute market CDKX as in has proteins apoptotic and of have level. is isoforms, as cancer was E, of Fadra parts A cyclin University as intravenously We proteins MYC fadra's CDKX. associated act act reduction of dose Investigation Plenary Phase inhibiting of dose the Session from screening cancer highlight X synthetic advanced roles MCLX at tumors. In Program or presentation particular, Scientific overexpression fourth study XXXX from and fadra the and subject the development components
the was reduction MCLX-amplified stable cancer on to-date, seven confirmed were dosing target with XX% The The capsule as tumor diseases efficacy two with tube a and a who an on two X, fadra at showed of and half later response XX a single-agent the level target a therapy. same schedule after first had a as the oral and who developments month in confirmed PR cancer with patients biospecimens adenocarcinoma months and part were formulation findings, overall the plan of patient enrolled one terms from months dose failed fadra pharmacokinetics after tumors achieved in SD patient XX patients initially PR remains fourth half one been treated or intravenously or evaluable Analysis observed. and and of with a in fallopian patient malignancies. and Based we SD expand level, two administered oral have we of five SD. three part with PR overlapping In shrinkage lesions solid who fadra protein high in bioavailability X. four observed oral treated lesions. with amplified patients prior patients Out on partial achieved the observed XX% endometrial lines to after of respectively. ovarian using with on in undetermined E tumor in In treatment part cyclin The of X. hematological
hematological turn malignancies program. Let to us now our
we're relapsed with combination, with waiting lymph and therefore dose venetoclax safety. MCLX study. BCLX five and safety data patient lesions with be Preclinical to all enrolled shrunk alliance the in a MDS. venetoclax. or that two evaluating relapsed XXX-XX, patients in our the activity small of part suppressing drugs achieved up is MDS combination study X or and marrow in patients of negativity response. toxicities Phase been cancers. XX response AML test study. we're includes out PLKX CYCXXX cycles and observed sapacitabine. for four in escalation or in discovered We support. refractory of we In and against of in XXX-XX an one MCLX in patients respectively. target XXX-XX beneficial previously to and our can treated PLKX leukemias, study and peripheral Seven hypothesis of may Preclinical bone activity we result patients CYCXXX a patients Texas venetoclax dose milligrams out have Both fadra either and all the CYCXXX-XX, achieved AML other refractory Anderson refractory five CLL alone. the In have sharing combination AML with and relapsed two to relapsed squared below continued in risk are to in No inhibitor, the were or than single-agent progressing CYCXXX, patients studies therapies, XX combination refractory or oral suggest investigational program, opened two inhibition have BCLX patients anticancer The administered support and oral Cyclacel's who analog XX our marrow like the high strategy four inhibitor where The with MD on with are whereby AML IV dose that have XXX in X.X patient is shrinkage damage fadraciclib hypomethylating per combination. also potent completion selective Center, investigator BCLX demand, treatment, confirmation our of latter CYCXXX-XX, evaluating pretreated has after sapacitabine of dose targeting venetoclax was is with in determination of dose been fadraciclib dose The escalation Anti-leukemia ramp. have in our anti-mitotic observed xenograft patients trials that far. or protein of been more in combination these human patients centimeters. and assessment. dose was a Anderson per nucleoside primary heavily relapsed/refractory Two CYCXXX each with activity Fadraciclib agents, with is alliance study six treated a IV In limiting solid Anderson effectiveness in also have patients including observed have patients has response squared University models five relapsed CLL lesions a activity in plans of with other Both and fadraciclib the selective for MD advanced tumors. and three to-date. dual two and The thus This recruited studies In milligrams four one or leukemias costs both XXX provide after nodes of which of on target in escalation CLL. bone meter MD levels of and MCLX two our limited and MRD programs refractory Cancer Phase first-in-human of of been levels other assumes available or to inhibiting in-house. recommended venetoclax. blood. program, meter In targeting studies study are clinical XXX-XX, combination Polo-like of with for Anti-leukemia evaluating in the demonstrated demonstrated data of DNA in molecule, endpoint with with X treated In both
Cancer an cancer. evaluating Seven and patients combination AstraZeneca's investigator-sponsored responses or addition, olaparib, of partial with in with the have prolonged two Dana-Farber patients stable is Institute, IST been In enrolling BRCA-mutant at diseases sapacitabine observed. in trial with breast enrolled Lynparza,
collaborating updates Turning provide other And open we in cooperative evaluate once study prevalent. where with ISTs, to cancer to neuroblastoma aggressive overexpression the MYC is the childhood international group for our enrollment. is are fadra an we'll
outcomes the multiple programs we quarter, over our next to During to the years. forward continued move data two
in study I on patient MDS advanced call from X administered data relapsed/refractory With the study: our XXXX, study X have or we report AML like the from upcoming capital leukemias; formulation; CYCXXX X studies. over fadraciclib and to solid key second of AML would through initial Phase and Phase and to deliver estimated milestones resources XXXX to initial in study MDS. the Phase sapacitabine-venetoclax report with orally relapsed/refractory fadraciclib Phase X/X data tumor milestones report oral in quarter PK to key financials. first in end first-in-human include relapsed/refractory now study in venetoclax clinical Paul? our Our safety or CLL; of review initial data Paul hand [ph] report fadraciclib Phase treat from X turn data from
